Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « AbsEn.i » - entrée « inhibitor »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
inhibitive < inhibitor < inhibitoren  Facettes :

List of bibliographic references indexed by inhibitor

Number of relevant bibliographic references: 343.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000014 (2020) Puja Mehta ; Jessica J. MansonWhat Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
000065 (2020) Ian Pirker [Suisse] ; Andrea Rubbert-Roth [Suisse] ; Johannes Von Kempis [Suisse] ; Martin Fehr [Suisse] ; Thomas Neumann [Suisse]Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy.
000069 (2020) Hanping Wang [République populaire de Chine] ; Ran Tian [République populaire de Chine] ; Peng Gao [République populaire de Chine] ; Qian Wang [République populaire de Chine] ; Li Zhang [République populaire de Chine]Tocilizumab for Fulminant Programmed Death 1 Inhibitor-Associated Myocarditis.
000070 (2020) Yasmine F. Ibrahim [Égypte] ; Rabab A. Moussa [Égypte] ; Asmaa M A. Bayoumi [Égypte] ; Al-Shaimaa F. Ahmed [Égypte]Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-κB/JNK: a possible role of P-glycoprotein.
000081 (2020) Francisco Vílchez-Oya [Espagne] ; Julia María Sánchez-Schmidt [Espagne] ; Anna Agustí [Espagne] ; Ana Pros [Espagne]The use of tocilizumab in the treatment of refractory eosinophilic fasciitis: a case-based review.
000089 (2020) Jacob J. Adashek [États-Unis] ; Shumei Kato [États-Unis] ; Scott M. Lippman [États-Unis] ; Razelle Kurzrock [États-Unis]The paradox of cancer genes in non-malignant conditions: implications for precision medicine
000090 (2020) Muneyoshi Futami [Japon] ; Keisuke Suzuki [Japon] ; Satomi Kato [Japon] ; Saori Ohmae [Japon] ; Yoshio Tahara [Japon] ; Masanori Nojima [Japon] ; Yoichi Imai [Japon] ; Takayuki Mimura [Japon] ; Yoshihiro Watanabe [Japon] ; Arinobu Tojo [Japon]The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells.
000107 (2020) Kyung Eun Kim ; Suwon Jeon ; Jisun Song ; Tae Sung Kim ; Min Kyung Jung ; Myun Soo Kim ; Sunyoung Park ; Seung Beom Park ; Jeong Min Park ; Hyun Jeong Park [Corée du Sud] ; Daeho ChoThe Novel Synthetic Peptide AESIS-1 Exerts a Preventive Effect on Collagen-Induced Arthritis Mouse Model via STAT3 Suppression
000109 (2020) Eric Toussirot [France]The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition
000122 (2020) Timothy M. Smith ; Anuj Tharakan ; Rebecca K. MartinTargeting ADAM10 in Cancer and Autoimmunity
000134 (2020) Ayush Gupta [Inde] ; Narendra Kumar Bagri [Inde] ; Saroj Kumar Tripathy [Inde] ; Adarsh Barwad [Inde] ; Ravi Hari Phulware [Inde] ; Pankaj Hari [Inde]Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis.
000135 (2020) Yixin Ally Wang [États-Unis] ; Misha Rosenbach [États-Unis]Successful treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis with tofacitinib: Report of case
000141 (2020) Adam Amlani [Canada] ; Claire Barber [Canada] ; Aurore Fifi-Mah [Canada] ; Jose Monzon [Canada]Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature.
000145 (2020) Yunze Li [République populaire de Chine] ; Yixin Yang [République populaire de Chine] ; Jinwan Guo [République populaire de Chine] ; Xuejiao Guo [République populaire de Chine] ; Zhiying Feng [République populaire de Chine] ; Xuli Zhao [République populaire de Chine]Spinal NF-kB upregulation contributes to hyperalgesia in a rat model of advanced osteoarthritis
000159 (2020) Cem Gabay [Suisse] ; Gerd R. Burmester [Allemagne] ; Vibeke Strand [États-Unis] ; Jérôme Msihid [France] ; Moshe Zilberstein [États-Unis] ; Toshio Kimura [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Susan H. Boklage [États-Unis] ; Jonathan Sadeh [États-Unis] ; Neil M. H. Graham [États-Unis] ; Anita Boyapati [États-Unis]Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
000168 (2020) Tsutomu Takeuchi [Japon] ; Yoshiya Tanaka [Japon] ; Sakae Tanaka [Japon] ; Atsushi Kawakami [Japon] ; Yeong-Wook Song [Corée du Sud] ; Yi-Hsing Chen [Taïwan] ; Mitsuhiro Rokuda [Japon] ; Hiroyuki Izutsu [Japon] ; Satoshi Ushijima [Japon] ; Yuichiro Kaneko [Japon] ; Yoshihiro Nakashima [Japon] ; Teruaki Shiomi [Japon] ; Emi Yamada [Japon]Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
000208 (2020) Natalia Maximova [Italie] ; Alessandra Maestro [Italie] ; Davide Zanon [Italie] ; Annalisa Marcuzzi [Italie]Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration
000226 (2020) Marie Febvre-James [France] ; Valérie Lecureur [France] ; Olivier Fardel [France]Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.
000229 (2020) Phyllis Chan [États-Unis] ; Jiajie Yu [États-Unis] ; Leslie Chinn [États-Unis] ; Marita Prohn [Pays-Bas] ; Jan Huisman [Pays-Bas] ; Brett Matzuka ; William Hanley [États-Unis] ; Katie Tuckwell [États-Unis] ; Angelica Quartino [États-Unis]Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis
000230 (2020) Josef S. Smolen [Autriche] ; Jung-Yoon Choe [Corée du Sud] ; Michael E. Weinblatt [États-Unis] ; Paul Emery [Royaume-Uni] ; Edward Keystone [Canada] ; Mark C. Genovese [États-Unis] ; Gihyun Myung [Corée du Sud] ; Evelyn Hong [Corée du Sud] ; Inyoung Baek [Corée du Sud] ; Jeehoon Ghil [Corée du Sud]Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis
000240 (2020) James Kalmuk [États-Unis] ; Jon Puchalla [États-Unis] ; Gong Feng [États-Unis] ; Anshu Giri [États-Unis] ; John Kaczmar [États-Unis]Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i -k "inhibitor" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i  \
                -Sk "inhibitor" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    inhibitor
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021